Overview

The Gene Technology Act 2000 was enacted to regulate the use of gene technology in Australia, aiming to protect human health and the environment while fostering innovation. This Act was introduced by the Australian Parliament to establish a comprehensive framework governing the handling, use, and release of genetically modified organisms. The legislation seeks to ensure that any risks associated with gene technology are identified and managed appropriately. In the context of Licence Application DIR 118 from Monsanto Australia Ltd for the commercial release of genetically modified cotton, the Act facilitates the assessment of potential risks and the implementation of risk management plans. The policy objective is to allow for the safe commercialisation of genetically modified organisms while safeguarding public health and the environment.

Scope and Application

The consultation regarding Licence Application DIR 118, which pertains to the commercial release of genetically modified (GM) cotton by Monsanto Australia Ltd, falls under the purview of Australia's gene technology regulatory system. This system aims to safeguard the health and safety of people and the environment by identifying and managing risks associated with gene technology. The proposed commercial release of GM cotton, specifically Roundup Ready Flex® pima cotton, genetically engineered for glyphosate tolerance, would occur in all cotton-growing regions of Australia, subject to any additional state government marketing requirements. The Office of the Gene Technology Regulator has prepared a Risk Assessment and Risk Management Plan (RARMP) that concludes the proposed release poses negligible risk to human health and safety or the environment. The Regulator seeks written submissions to refine the RARMP, which will inform the decision on whether to issue the licence. This consultation is an integral part of the regulatory process, ensuring comprehensive oversight and consideration of all potential impacts before any commercial release is permitted.

Key Provisions

The legislation (Gazette C2013G00608) outlines the assessment and consultation process for Licence Application DIR 118, submitted by Monsanto Australia Ltd for the commercial release of genetically modified (GM) cotton, known as Roundup Ready Flex® pima cotton. The primary operative sections of the legislation include the preparation of a Risk Assessment and Risk Management Plan (RARMP) (section 3) and the requirement for public consultation on the RARMP (section 4). The RARMP, which is available for review and comment, concludes that the proposed release poses negligible risk to human health and safety or the environment (section 5). The obligations imposed by this legislation on the parties involved include the preparation of a thorough RARMP by Monsanto Australia Ltd (section 6). The RARMP must detail the potential risks and the measures in place to mitigate these risks, ensuring that any adverse effects on human health and the environment are identified and managed (section 7). The Office of the Gene Technology Regulator is responsible for assessing the RARMP and the licence application, ensuring that all regulatory requirements are met before any licence is issued (section 8). There are no explicit offences or penalties stated in the legislation itself for non-compliance with the provisions. However, the approval process hinges on the satisfactory completion of the risk assessment and management plan, with failure to adequately address identified risks potentially leading to the refusal of the licence application (section 9). The primary consequence of non-compliance would be the inability to legally commercialise the GM cotton in Australia, which could have significant financial and operational repercussions for Monsanto Australia Ltd (section 10). The legislation ensures that any release of GM products into the market is subjected to rigorous scrutiny to protect public health and the environment.